Thus, lower levels of CSF CysC manifested in patients with AD, DLB and AF-GP may result in decreased ability to inhibit the activity of cathepsins, impaired cytoprotective response to prevent neurodegeneration in various pathological conditions, decreased level of neurogenesis and decreased ability to inhibit neuronal Αβ aggregation and deposition. This evidence concerns the gene CTSS and Lewy body dementia.